Pharmaceuticals

BIOCAUSE HEILEN PHARMA

BIOCAUSE HEILEN PHARMA released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue CNY 120.16 M, actual EPS CNY 0.02

BIOCAUSE HEILEN PHARMA FY2026 Q1 Earnings Release on April 23 After-Market BJT

BIOCAUSE HEILEN PHARMA released FY2025 earnings on March 30 After-Market (BJT), actual revenue CNY 453.31 M, actual EPS CNY 0.08

BIOCAUSE HEILEN PHARMA released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue CNY 134.41 M, actual EPS CNY 0.0285

BIOCAUSE HEILEN PHARMA to Release FY2025 Annual Earnings on March 31, 2026 After-Market (BJT)

BIOCAUSE HEILEN PHARMA released FY2025 Q3 earnings on October 27 Pre-Market (BJT), actual revenue CNY 84.13 M, actual EPS CNY 0.0066

BIOCAUSE HEILEN PHARMA released FY2025 9 Months Earnings on October 27 Pre-Market (BJT), actual revenue CNY 318.9 M, actual EPS CNY 0.0423

BIOCAUSE HEILEN PHARMA to Release FY2025 Q3 Earnings on October 28, Pre-Market BJT

BIOCAUSE HEILEN PHARMA released FY2025 Q2 earnings on July 31 Pre-Market (BJT), actual revenue CNY 120.32 M, actual EPS CNY 0.0228

BIOCAUSE HEILEN PHARMA released FY2025 Semi-Annual Earnings on July 31 Pre-Market (BJT), actual revenue CNY 234.77 M, actual EPS CNY 0.0357

BIOCAUSE HEILEN PHARMA to Release FY2025 Semi-Annual Earnings on August 1, 2025 (BJT)

HenDi Pharmaceutical's ESG Rating Results Announced

Handy Pharmaceutical Obtains Registration Certificate for Ibuprofen Suspension

HenDi Pharmaceutical's Subsidiary Passes FDA cGMP Inspection

Chemical Pharmaceutical Stocks Rise, Hengdi Pharmaceutical and Xinhua Pharmaceutical Lead

BIOCAUSE HEILEN PHARMA released FY2025 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 114.45 M, actual EPS CNY 0.02

Hendee Pharmaceutical Reports Significant Earnings Decline

Handy Pharmaceutical Receives Approval for Arginine Ibuprofen Listing Application

BIOCAUSE HEILEN PHARMA released FY2024 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 111.87 M, actual EPS CNY 0.0401

BIOCAUSE HEILEN PHARMA released FY2024 earnings on April 23 After-Market BJT, actual revenue CNY 445.86 M, actual EPS CNY 0.32

301211

BIOCAUSE HEILEN PHARMA released its Q3 2025 report, with operating revenue for the first three quarters amounting to 319 million yuan, a year-on-year decrease of 4.52%. The net profit attributable to the parent company was 20.9334 million yuan, a year-on-year decline of 71.96%; the net profit after deducting non-recurring gains and losses was 543,800 yuan, a year-on-year decrease of 99.14%. The basic earnings per share were 0.05 yuan

Zhitong

BIOCAUSE HEILEN PHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 20.9334 million yuan, a decrease of 71.96%

According to the Zhitong Finance APP, BIOCAUSE HEILEN PHARMA announced that the company recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration, for the drug Febuxostat Tablets. Febuxostat Tablets are a xanthine oxidase inhibitor, primarily used for the long-term treatment of hyperuricemia and gout patients (including urate-lowering treatment after acute attacks of gouty arthritis)

BIOCAUSE HEILEN PHARMA: Febuxostat tablets have obtained a drug registration certificate

According to the Zhitong Finance APP, BIOCAUSE HEILEN PHARMA announced that the company recently received the "Approval Notice for the Market Application of Chemical Raw Materials" issued by the National Medical Products Administration for Metoclopramide Hydrochloride. Metoclopramide Hydrochloride is a dopamine receptor antagonist primarily used to relieve symptoms of nausea and vomiting, and it can also promote gastrointestinal motility to improve issues such as dyspepsia and delayed gastric emptying

BIOCAUSE HEILEN PHARMA: Hydrochloride of Methoxychlorpromazine has received approval for the listing application of chemical raw materials

BIOCAUSE HEILEN PHARMA released its semi-annual report for 2025, with operating revenue of 235 million yuan, a year-on-year decrease of 2.93%; net profit attributable to the parent company was 18.5471 million yuan, a year-on-year decline of 72.92%. After deducting non-recurring gains and losses, the net profit was 4.4162 million yuan, a year-on-year decrease of 93.21%. The basic earnings per share were 0.06 yuan. The company plans to distribute 4.5 additional shares for every 10 shares to all shareholders and actively promote the implementation of fundraising investment projects, including the safety and environmental upgrade technical reform project for the hydrolysis and acidification position of ibuprofen raw materials and the construction of high-end pharmaceutical formulation internationalization projects

BIOCAUSE HEILEN PHARMA released its half-year performance, with a net profit attributable to the parent company of 18.5471 million yuan, a decrease of 72.92%

002653

002370

000153

600276

Pharmaceutical and medical stocks continue to strengthen, with FENGYUAN PHARMACEUTICAL hitting the limit up, Hengrui Pharma rising over 7%, and Haisco, BIOCAUSE HEILEN PHARMA, Yatai pharm, and Yirui Biologics also following suit

Wallstreetcn

Haisco

Yatai pharm

FENGYUAN PHARMACEUTICAL

Hengrui Pharma

300086

002022

300254

002030

The hepatitis concept sector saw a short-term surge, with KHB hitting the limit up, and C&Y Pharmaceutical, BIOCAUSE HEILEN PHARMA, DAJY, Yatai pharm, and Honz all rising

Honz

C&Y Pharmaceutical

DAJY

The hepatitis concept sector has seen a short-term surge

301182

688425

On Monday, a total of 16 companies had their restricted shares unlocked, with a total unlock volume of 4.291 billion shares and an unlock market value of 25.318 billion yuan. CRCHI, BIOCAUSE HEILEN PHARMA, and Huaru Technology had the highest unlock volumes, at 3.856 billion shares, 216 million shares, and 7.1625 million shares, respectively. In terms of unlock market value, CRCHI, BIOCAUSE HEILEN PHARMA, and CARVE had unlock market values of 15.229 billion yuan, 3.627 billion yuan, and 1.969 billion yuan, respectively. Five companies had an unlock ratio exceeding 10%, with BIOCAUSE HEILEN PHARMA, CRCHI, and CARVE having unlock ratios of 75.0%, 72.29%, and 60.08%, respectively

CARVE

CRCHI

Huaru

Overview of A-share lock-up stock release: Lock-up stocks with a market value of 25.318 billion yuan are released today

According to the Zhitong Finance APP, BIOCAUSE HEILEN PHARMA announced that the company recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration ("NMPA"), involving the product: "Ibuprofen Suspension". The announcement stated that the registration classification of the ibuprofen suspension is Category 4 chemical drugs, which were reviewed and approved according to the technical requirements consistent with the quality and efficacy of the reference preparation, and after approval, it is deemed to have passed the consistency evaluation of the quality and efficacy of generic drugs

BIOCAUSE HEILEN PHARMA: Ibuprofen suspension has obtained the drug registration certificate

BIOCAUSE HEILEN PHARMA recently received the "Drug Registration Certificate" approved by the National Medical Products Administration, registering the drug as Torasemide Injection. This is a highly effective, long-acting loop diuretic suitable for the long-term management of heart failure, liver cirrhosis, and renal edema, with high oral bioavailability and lower potassium risk. The drug registration is classified as a Class 3 chemical drug, and upon approval, it is considered to have passed the consistency evaluation of generic drug quality and efficacy

BIOCAUSE HEILEN PHARMA received a drug registration certificate

BIOCAUSE HEILEN PHARMA's wholly-owned subsidiary, Wuhan Baike Drug Development Co., Ltd., underwent a cGMP on-site inspection by the U.S. FDA from March 10 to 14, 2025, and recently received the on-site inspection report issued by the FDA, confirming that it passed the inspection

BIOCAUSE HEILEN PHARMA: Encyclopedia Pharmaceuticals passes on-site inspection by the US FDA

BIOCAUSE HEILEN PHARMA(301211.SZ)